Dade Behring launches homocysteine assay in Europe:
This article was originally published in Clinica
Dade Behring has introduced for sale in Europe a homocysteine assay for determining a patient's risk of heart attack and stroke. The assay, which is manufactured by Dade's marketing partner Axis-Shield, is designed for use on the company's BNII and BN ProSpec systems. Up to 47% of patients with symptoms of cardiovascular disease show elevated levels of homocysteine, the Deerfield, Illinois firm said. The company added that it may also run the homocysteine test in conjunction with its CardioPhase hsCRP, cholesterol, lipids, Apo A1/Apo B, Lp(a), and microalbuminuria tests. The cardiovascular risk assessment panel is run in both routine and specialised laboratories.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.